Pathalys Pharma, founded with a mission to innovate therapeutics for advanced chronic kidney disease (CKD), focuses on developing clinical biopharmaceutical solutions to improve the lives of patients with late-stage CKD. The company is dedicated to addressing the unmet medical needs of this patient population, primarily through the development of its lead product candidate, upacicalcet, designed for patients receiving hemodialysis.
Notable investors include Abingworth, which led a significant funding round to support Pathalys' initiatives. A key achievement for the company is the early enrollment of the first patient in their pivotal phase program for upacicalcet, ahead of schedule, in collaboration with Launch Therapeutics. This milestone underscores Pathalys Pharma's commitment to accelerating the availability of effective treatments for CKD, potentially improving outcomes and quality of life for many patients.
